Anti-tumor activity of orally available cyclic peptide LUNA18 through direct pan-RAS inhibition across diverse RAS genetic alterations

Molecular Cancer Therapeutics · Published 2026-07-30 · DOI 10.1158/1535-7163.mct-26-0262

Authors (18)

Hitoshi Sase, Saki Michisaka, Yukako Tachibana, Masami Hasegawa, Toshihiko Fujii, Kana Takei, Tomoko Kanei, Naoaki Murao, Ryuichi Komatsu, Kentaro Asanuma, Shino Kuramoto, Norihito Shibahara, Atsushi Ohta, Mikimasa Tanada, Takuya Shiraishi, Hitoshi Iikura, Takehisa Kitazawa, Hiroshi Tanaka

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Sase, H., Michisaka, S., Tachibana, Y., et al. (2026). Anti-tumor activity of orally available cyclic peptide LUNA18 through direct pan-RAS inhibition across diverse RAS genetic alterations. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-26-0262

Related articles